ArticleAntibiotics (Basel, Switzerland)2023
In Vitro Synergistic Activity of Antimicrobial Combinations against Carbapenem- and Colistin-Resistant
Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.The Journal of antimicrobial chemotherapy · 2025Pooled it
- Pooled it
- BamA as a next-generation antibacterial target: mechanistic insights, inhibitor landscape, and rational drug design strategies.RSC advances · 2026Review
- Breaking the antimicrobial resistance dilemma: marine natural products, a treasure trove for the development of new anti-Marine life science & technology · 2026Review
- Synergistic and antagonistic interactions between colistin and cell-free supernatants of Lactobacillus species against clinical isolates of Acinetobacter baumannii.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Article
- Molecular Characterization of Colistin-Resistant ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- A Comprehensive Review of the Multitarget Effects of Subinhibitory Concentrations of Essential Oils Against Salmonella.Comprehensive reviews in food science and food safety · 2026Review
- In Vitro Evaluation of Colistin-Meropenem Activity Against XDR and PDR Carbapenemase-ProducingPathogens (Basel, Switzerland) · 2026Article
- Treating Extensively Drug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Therapeutic strategies against biofilm-associated multidrug-resistantFrontiers in microbiology · 2026Review
- Restoring colistin sensitivity in colistin-resistant gram-negative bacteria: combinatorial use of α-terpineol and colistin.Microbiology spectrum · 2025Article
- Synergistic drug strategy against mastitis-associated MRSA strains.Future microbiology · 2025Article
- Antimicrobial Resistance Profiles of Multidrug-Resistant Pathogens in a Military Hospital: A Three-Year Study.Cureus · 2025Article
- In Vitro Evaluation of Antimicrobial Synergy Against Multidrug-Resistant Gram-Negative Paediatric Bloodstream Pathogens in South Africa.Antibiotics (Basel, Switzerland) · 2025Article
- Salvage Therapy Against Infections of MDRMicroorganisms · 2025Article
- Development of polymyxin- and aminoglycoside-based outer membrane permeabilizers: a review.Frontiers in microbiology · 2025Review
- Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistantMicrobiology spectrum · 2024Article
- Co-Administration of High-Dose Nebulized Colistin forAntibiotics (Basel, Switzerland) · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymyxins are commonly used as the last resort for the treatment of MDR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.